Cargando…

In vitro evaluation of folic acid-conjugated redox-responsive mesoporous silica nanoparticles for the delivery of cisplatin

The use of cisplatin(IV) prodrugs for the delivery of cisplatin have gained significant attention, because of their low toxicity and reactivity. Recent studies have shown that targeted cisplatin(IV)-prodrug nanoparticle-based delivery systems can improve the internalization of the cisplatin(IV) prod...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarez-Berríos, Merlis P, Vivero-Escoto, Juan L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125786/
https://www.ncbi.nlm.nih.gov/pubmed/27920531
http://dx.doi.org/10.2147/IJN.S118196
_version_ 1782470017546190848
author Alvarez-Berríos, Merlis P
Vivero-Escoto, Juan L
author_facet Alvarez-Berríos, Merlis P
Vivero-Escoto, Juan L
author_sort Alvarez-Berríos, Merlis P
collection PubMed
description The use of cisplatin(IV) prodrugs for the delivery of cisplatin have gained significant attention, because of their low toxicity and reactivity. Recent studies have shown that targeted cisplatin(IV)-prodrug nanoparticle-based delivery systems can improve the internalization of the cisplatin(IV) prodrug. We hypothesized that folic acid-conjugated mesoporous silica nanoparticles (MSNs) containing cisplatin(IV) prodrug could target cancer cells that overexpress the folate receptor and deliver the active cisplatin drug upon intracellular reduction. To prove this hypothesis, internalization and localization studies in HeLa cancer cells were performed using flow cytometry and confocal microscopy. The ability of MSNs to escape from the endolysosomal compartments, the formation of DNA adducts, and the cytotoxic effects of the MSNs were also evaluated. Our results confirmed that this MSN-based delivery platform was capable of delivering cisplatin into the cytosol of HeLa cells, inducing DNA adducts and subsequent cell death.
format Online
Article
Text
id pubmed-5125786
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-51257862016-12-05 In vitro evaluation of folic acid-conjugated redox-responsive mesoporous silica nanoparticles for the delivery of cisplatin Alvarez-Berríos, Merlis P Vivero-Escoto, Juan L Int J Nanomedicine Original Research The use of cisplatin(IV) prodrugs for the delivery of cisplatin have gained significant attention, because of their low toxicity and reactivity. Recent studies have shown that targeted cisplatin(IV)-prodrug nanoparticle-based delivery systems can improve the internalization of the cisplatin(IV) prodrug. We hypothesized that folic acid-conjugated mesoporous silica nanoparticles (MSNs) containing cisplatin(IV) prodrug could target cancer cells that overexpress the folate receptor and deliver the active cisplatin drug upon intracellular reduction. To prove this hypothesis, internalization and localization studies in HeLa cancer cells were performed using flow cytometry and confocal microscopy. The ability of MSNs to escape from the endolysosomal compartments, the formation of DNA adducts, and the cytotoxic effects of the MSNs were also evaluated. Our results confirmed that this MSN-based delivery platform was capable of delivering cisplatin into the cytosol of HeLa cells, inducing DNA adducts and subsequent cell death. Dove Medical Press 2016-11-23 /pmc/articles/PMC5125786/ /pubmed/27920531 http://dx.doi.org/10.2147/IJN.S118196 Text en © 2016 Alvarez-Berríos and Vivero-Escoto. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Alvarez-Berríos, Merlis P
Vivero-Escoto, Juan L
In vitro evaluation of folic acid-conjugated redox-responsive mesoporous silica nanoparticles for the delivery of cisplatin
title In vitro evaluation of folic acid-conjugated redox-responsive mesoporous silica nanoparticles for the delivery of cisplatin
title_full In vitro evaluation of folic acid-conjugated redox-responsive mesoporous silica nanoparticles for the delivery of cisplatin
title_fullStr In vitro evaluation of folic acid-conjugated redox-responsive mesoporous silica nanoparticles for the delivery of cisplatin
title_full_unstemmed In vitro evaluation of folic acid-conjugated redox-responsive mesoporous silica nanoparticles for the delivery of cisplatin
title_short In vitro evaluation of folic acid-conjugated redox-responsive mesoporous silica nanoparticles for the delivery of cisplatin
title_sort in vitro evaluation of folic acid-conjugated redox-responsive mesoporous silica nanoparticles for the delivery of cisplatin
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125786/
https://www.ncbi.nlm.nih.gov/pubmed/27920531
http://dx.doi.org/10.2147/IJN.S118196
work_keys_str_mv AT alvarezberriosmerlisp invitroevaluationoffolicacidconjugatedredoxresponsivemesoporoussilicananoparticlesforthedeliveryofcisplatin
AT viveroescotojuanl invitroevaluationoffolicacidconjugatedredoxresponsivemesoporoussilicananoparticlesforthedeliveryofcisplatin